Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1564 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Hyperostosis Corticalis Generalisata, Benign Form Of Worth, With Torus Palatinus | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81406, 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
LRP5 related high bone density phenotypes - Hyperostosis corticalis generalisata, benign form of worth, with torus palatinus or endosteal hyperostosis (MIM 144750) is an autosomal dominant disorder caused by mutations in the LDL receptor-related protein 5 (LRP5) gene. The main findings include cortical thickening of the long bones and progressive enlargement of the mandible with decreased gonial angle and the development of torus palatinus. The long bones are not altered in shape but are resistant to fractures. The torus palatinus may lead to malocclusion and tooth loss. The skeleton is usually normal in childhood and the patients are of normal height and proportion. During adolescence the face begins to flatten and the mandibular and palate changes occur. Increased density of the calvarium may be evident on radiographs. Osteopetrosis, autosomal dominant 1 (OPTA1; MIM 607634) is characterized by diffuse osteosclerosis with pronounced involvement of cranial bones. The cranial vault may be enlarged and a conductive hearing loss may be present. OPTA1 is not associated with an increased fracture rate. OPTA1 is caused by gain of function mutations in the gene encoding the LDL receptor-related protein 5 (LRP5). See also osteopetrosis, autosomal dominant 2 (OPTA2; MIM 166600) caused by mutations in the CLCN7 gene. Van Buchem disease, type 2 (VBCH2; MIM 607636) is an autosomal dominant, high bone density disorder caused by mutations in the LDL receptor-related protein 5 (LRP5) gene. Clinical features include an enlarged mandible, increased calvarial thickness, cranial osteosclerosis and thickened cortices of long bones. The clinical findings in VBCH2 are similar to those in hyperostosis corticalis generalisata. It has been suggested that these high bone density disorders represent a continuum. The detection of a shared LRP5 mutation in patients with VBCH2 and hyperostosis corticalis generalisata indicates that this is indeed the case. It should be noted that an autosomal recessive variant of Van Buchem disease is recognized. Patients with autosomal recessive Van Buchem disease are more severely affected and present with facial nerve palsies. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| LRP5 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 144750 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Metabolic and Endocrine, Skeletal Disorders | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.